If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

Drugmaker GSK has been tapped as a potential target for activist investors, according to Bloomberg, which noted that shares had fallen roughly 19% since spinning off its consumer health business in ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

If you had any doubt about the “vibe shift” in 2025 Washington, look no further than the impact the Make America Healthy ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price ...

DIA's Europe Annual Meeting, featuring discussions from top European health leaders, will be held March 18-20 in Basel.

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...